Recent Posts

1. 

   karuna deal

   i referred two external who sell in neuro for abbvie neither got calls yet, odd?

   Bristol-Myers Squibb

   anonymous

   Apr 23, 2024 at 11:49 AM

2. 

   abbott diabetics

   Amen, amen, amen. It’s always “DEI” when a bad hire is a woman or minority. But when the bad hire into leadership is a white male, which happens ALL THE TIME, it’s never discussed that the privilege of the job assignment was given to the white...

   Abbott

   anonymous

   Apr 23, 2024 at 11:43 AM

3. 

   Hey AGM’s

   Exactly!

   Bayer

   anonymous

   Apr 23, 2024 at 11:41 AM

4. 

   Miebo 20$ otc Europe and 750$ WAC U.S.A.

   Miebo vs Evotears Good morning, all! Last month my doc prescribed me Miebo, thinking it would help me significantly with my evaporative dry eye. I was shocked when the ticket price was 250 per month and will go up to 750 after I exhaust the...

   Bausch & Lomb

   anonymous

   Apr 23, 2024 at 11:28 AM

5. 

   Sanofi gears up for approval of its BTK inhibitor, meets Phase III endpoint

   via Sanofi’s rilzabrutinib has found success and met the primary endpoint in the Phase III LUNA trial in heavily pre-treated immune thrombocytopenia (ITP) patients. The French company also plans to file for approval of the rilzabrutinib in the...

   Pharma/Biotech Companies - In the News

   cafead

   Apr 23, 2024 at 11:22 AM

6. 

   Sotyktu floundering

   Yes, but here is the thing you guys don’t understand these managers and directors will always have the last laugh. They will get a crazy severances. They will take their fugazzi Certificates from a weekend course at Harvard business Or Wharton...

   Bristol-Myers Squibb

   anonymous

   Apr 23, 2024 at 11:22 AM

7. 

   Good riddance Mike Bell

   100% spot on. Embarrassment. He’s been conditioned to get paid to say what he wants, most of the time like a fool.

   Takeda

   anonymous

   Apr 23, 2024 at 11:22 AM

8. + Show More